Gamma-herpesviruses can cancers. For example, Epstein-Barr virus (EBV) causes B cell Burkitt's lymphoma and nasopharyngeal carcinoma. EBV infection is endemic worldwide with a sero-prevalence of 75-95%. Our understanding of how EBV infects in vivo and how it might be controlled is limited. For example, how EBV enters the host is still a contested debate. This has made vaccination a distant challenge. Vaccine trials to date have reduced the symptoms of primary infection (infectious mononucleosis) but not the longterm viral loads that likely lead to cancers. The species specificity of EBV has made new vaccines difficult to develop. Murid-herpesvirus 4 (strain MHV-68), readily infects inbred laboratory mice, and has provided an accessible way to understand gamma-herpesvirus infection and control. Like EBV, it persists in memory B cells. Live-attenuated MHV-68 that lacks the ORF73 open reading frame, and so is deficient in latency and persistence, protects mice against longterm wild type infection. Dissecting natural and vaccine-induced infection control has identified distinct roles for CD4 + T cells, CD8 + T cells and antibody. CD4 + T cells play a particular role in controlling chronic lytic infection. As yet, the immune effectors responsible for controlling latency remain ill-defined. CD8 + T cells specific for latent viral antigens play some role, but vaccination to prime these cells has not reduced long-term viral loads. Recently, cytomegaloviruses have gained prominence as vaccine vectors. To test protection by CD4 + T cell priming, a recombinant murine cytomegalovirus that expresses membrane bound ovalbumin from the viral genome was used to vaccinate against a recombinant MHV-68 that expresses the same membrane bound ovalbumin from a lytic promoter. Vaccinated mice controlled lytic infection but failed to reduce long-term infection. Nor was a combination of CD4 + and CD8 + T cell priming fully effective. In trying to improve recombinant cytomegalovirus-based priming, MHC class II down-regulation was noted in infected cells, along with relatively weak CD4 + T cell priming. This down-regulation was found to depend on the viral M78 gene. M78-deficient MCMV was characterised in vitro and in vivo. More than one defect was identified, but a significant component was found to be CD4 + T cell-dependent. This represents a possible future basis for better cytomegalovirus-mediated CD4 + T cell priming, and so better protection against long-term gamma-herpesvirus infection. Declaration by author This thesis is composed of my original work, and contains no material previously published or written by another person except where due reference has been made in the text. I have clearly stated the contribution by others to jointly-authored works that I have included in my thesis. I have clearly stated the contribution of others to my thesis as a whole, including statistical assistance, survey design, data analysis, significant technical procedures, professional editorial advice, financial support and any other original researc...